William Blair initiated coverage on shares of F-star Therapeutics (NASDAQ:FSTX) in a research note issued to investors on Thursday, The Fly reports. The firm set an “outperform” rating on the stock.

A number of other brokerages have also recently commented on FSTX. Laidlaw assumed coverage on F-star Therapeutics in a research report on Tuesday, March 30th. They set a “buy” rating and a $32.00 price target for the company. Zacks Investment Research lowered F-star Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, April 1st. Finally, HC Wainwright started coverage on F-star Therapeutics in a research note on Monday, March 8th. They set a “buy” rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $33.50.

Shares of FSTX opened at $10.20 on Thursday. The stock’s 50-day moving average price is $9.90. F-star Therapeutics has a one year low of $3.56 and a one year high of $15.50. The firm has a market cap of $44.03 million, a PE ratio of -1.47 and a beta of 1.78.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arcadia Investment Management Corp MI purchased a new position in shares of F-star Therapeutics during the 4th quarter valued at about $30,000. Private Capital Advisors Inc. purchased a new position in shares of F-star Therapeutics in the 4th quarter valued at about $129,000. Endurant Capital Management LP purchased a new position in shares of F-star Therapeutics in the 4th quarter valued at about $202,000. Parsons Capital Management Inc. RI purchased a new position in shares of F-star Therapeutics in the 4th quarter valued at about $228,000. Finally, BlackRock Inc. purchased a new position in shares of F-star Therapeutics in the 4th quarter valued at about $443,000. Institutional investors and hedge funds own 67.80% of the company’s stock.

F-star Therapeutics Company Profile

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1.

Featured Story: What are gap-up stocks?

The Fly

Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.